This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Obesity Science & Innovation
September 16-17, 2025
Hynes Convention CenterBoston

From innovation to impact: understand leading and emerging obesity therapeutics that are transforming lives and reshaping global wellness

Call for Speakers - Limited Speaking Opportunities

Research is underway for Informa's inaugural Obesity Science & Innovation event, held September 16-17, 2025 as part of Biotech Week Boston. Sign up for email updates below and contact Kaitlin Daily at kaitlin.dailey@informa.com for speaking enquiries.

Dive into the forefront of obesity drug development

Designed for researchers from biotech and pharma, the event spotlights cutting-edge clinical advancements in GLP-1 agonism, as well as emerging next-gen approaches and modalities. Connect with peers, explore emerging science, and collaborate on developing safe, effective and durable treatments for obesity and its related comorbidities.

GLP-1 CLINICAL HIGHLIGHTS

Exploring updates from leading GLP-1, dual- and tri-agonist clinical trials, across peptide and small molecule drug modalities.

BIOLOGY & TRANSLATION

Diving into the complex biology of obesity, including the shaping of translational strategies to accelerate clinical development of therapeutics.

MAINTENANCE INNOVATION

Highlighting approaches to enhance patient adherence and weight-loss maintenance, including development of oral formulations and combating sarcopenia.

BEYOND GLP-1: RAPID FIRE

Showcasing next generation modalities and approaches in obesity therapeutics, hear fromemerging early-stage innovators who are looking at solutions beyond GLP-1, such as inflammasome inhibitors, β2AR and cannabinoid receptor agonists

RNA-BASED THERAPEUTICS

Exploring RNA-based therapeutics for obesity, including siRNA, non-coding RNA and editing approaches.

Forums

  • MARKET ACCESS & REIMBURSEMENT
  • MANUFACTURING & PACKAGING
  • INVESTMENT & IP STRATEGY